Verastem Oncology’s Announcement Regarding AVMAPKI (Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma)

TOKYO, May 23, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Verastem Oncology issued a press release on AVMAPKI TM (generic name: avutometinib) about positive updated results from RAMP 205 evaluating avutometinib plus defactinib in combination with standard-of-care chemotherapy in frontline metastatic pancreatic ductal adenocarcinoma on May 22, 2025. AVMAPKI was created by Chugai, and its clinical development is being conducted by Verastem Oncology. Please refer to the link below for details of the Verastem Oncology’s press release: Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-positive-updated-results-ramp-205 Trademarks used or mentioned in this release are protected by laws.

The release as fetched from its publisher. chugai-pharm.co.jp ↗